Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:KNSA NASDAQ:MOR NASDAQ:NRIX NYSE:OGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKNSAKiniksa Pharmaceuticals International$38.47+0.9%$34.87$17.82▼$39.12$2.84B0.16640,110 shs128,830 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/ANRIXNurix Therapeutics$9.99+1.6%$9.61$8.18▼$29.56$762.59M2.33895,233 shs549,399 shsOGNOrganon & Co.$10.24-3.4%$9.88$8.01▼$19.05$2.66B0.634.34 million shs1.41 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKNSAKiniksa Pharmaceuticals International-0.44%-1.83%+6.75%+32.36%+60.64%MORMorphoSys0.00%0.00%0.00%0.00%0.00%NRIXNurix Therapeutics-1.21%+6.39%-0.81%-25.42%-54.36%OGNOrganon & Co.-2.24%-0.78%+2.24%+6.40%-41.52%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeKNSAKiniksa Pharmaceuticals International$38.47+0.9%$34.87$17.82▼$39.12$2.84B0.16640,110 shs128,830 shsMORMorphoSys$18.96$18.96$4.18▼$19.50$2.86B1.21.02 million shsN/ANRIXNurix Therapeutics$9.99+1.6%$9.61$8.18▼$29.56$762.59M2.33895,233 shs549,399 shsOGNOrganon & Co.$10.24-3.4%$9.88$8.01▼$19.05$2.66B0.634.34 million shs1.41 million shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceKNSAKiniksa Pharmaceuticals International-0.44%-1.83%+6.75%+32.36%+60.64%MORMorphoSys0.00%0.00%0.00%0.00%0.00%NRIXNurix Therapeutics-1.21%+6.39%-0.81%-25.42%-54.36%OGNOrganon & Co.-2.24%-0.78%+2.24%+6.40%-41.52%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceKNSAKiniksa Pharmaceuticals International 2.78Moderate Buy$44.2915.12% UpsideMORMorphoSys 0.00N/AN/AN/ANRIXNurix Therapeutics 2.76Moderate Buy$29.07191.01% UpsideOGNOrganon & Co. 2.50Moderate Buy$17.3369.35% UpsideCurrent Analyst Ratings BreakdownLatest NRIX, OGN, MOR, and KNSA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025KNSAKiniksa Pharmaceuticals InternationalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)10/8/2025NRIXNurix TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025OGNOrganon & Co.Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)10/6/2025KNSAKiniksa Pharmaceuticals InternationalZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold9/29/2025KNSAKiniksa Pharmaceuticals InternationalTD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$60.009/27/2025KNSAKiniksa Pharmaceuticals InternationalWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingHold (C)9/27/2025NRIXNurix TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025OGNOrganon & Co.Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)9/25/2025KNSAKiniksa Pharmaceuticals InternationalWells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$42.00 ➝ $45.008/26/2025NRIXNurix TherapeuticsBaird R WSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy7/31/2025NRIXNurix TherapeuticsOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$32.00 ➝ $30.00(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookKNSAKiniksa Pharmaceuticals International$423.24M6.74N/AN/A$6.60 per share5.83MORMorphoSys$238.28M11.99N/AN/A$0.35 per share54.17NRIXNurix Therapeutics$54.55M14.00N/AN/A$7.44 per share1.34OGNOrganon & Co.$6.40B0.42$4.65 per share2.20$1.83 per share5.59Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateKNSAKiniksa Pharmaceuticals International-$43.19M$0.04958.24153.88N/A0.90%1.05%0.80%11/4/2025 (Estimated)MORMorphoSys-$205.35M-$3.48N/AN/AN/A-226.79%-694.31%-22.55%N/ANRIXNurix Therapeutics-$193.57M-$2.61N/AN/AN/A-234.57%-45.26%-34.71%10/10/2025 (Estimated)OGNOrganon & Co.$864M$2.693.802.740.9811.15%163.88%6.99%10/30/2025 (Estimated)Latest NRIX, OGN, MOR, and KNSA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails11/4/2025Q3 2025KNSAKiniksa Pharmaceuticals International$0.31N/AN/AN/AN/AN/A10/30/2025Q3 2025OGNOrganon & Co.$0.93N/AN/AN/A$1.57 billionN/A10/10/2025Q3 2025NRIXNurix Therapeutics-$0.84N/AN/AN/A$16.06 millionN/A8/5/2025Q2 2025OGNOrganon & Co.$0.94$1.00+$0.06$0.56$1.55 billion$1.59 billion7/29/2025Q2 2025KNSAKiniksa Pharmaceuticals International$0.18$0.23+$0.05$0.23$145.21 million$156.80 million7/9/2025Q2 2025NRIXNurix Therapeutics-$0.79-$0.52+$0.27-$0.52$16.26 million$44.06 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/AMORMorphoSysN/AN/AN/AN/AN/ANRIXNurix TherapeuticsN/AN/AN/AN/AN/AOGNOrganon & Co.$0.080.78%N/A2.97%N/ALatest NRIX, OGN, MOR, and KNSA DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date8/5/2025OGNOrganon & Co.quarterly$0.020.9%8/15/20258/15/20259/11/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioKNSAKiniksa Pharmaceuticals InternationalN/A3.573.16MORMorphoSys4.981.381.38NRIXNurix TherapeuticsN/A6.826.82OGNOrganon & Co.11.981.651.13Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipKNSAKiniksa Pharmaceuticals International53.95%MORMorphoSys18.38%NRIXNurix TherapeuticsN/AOGNOrganon & Co.77.43%Insider OwnershipCompanyInsider OwnershipKNSAKiniksa Pharmaceuticals International53.48%MORMorphoSys0.05%NRIXNurix Therapeutics7.40%OGNOrganon & Co.1.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableKNSAKiniksa Pharmaceuticals International22074.11 million34.48 millionOptionableMORMorphoSys730150.62 million150.55 millionNot OptionableNRIXNurix Therapeutics30076.45 million70.79 millionOptionableOGNOrganon & Co.4,000259.97 million256.33 millionNot OptionableNRIX, OGN, MOR, and KNSA HeadlinesRecent News About These CompaniesInvestors Heavily Search Organon & Co. (OGN): Here is What You Need to Know5 hours ago | zacks.comBrokerages Set Organon & Co. (NYSE:OGN) Target Price at $17.33October 8 at 3:17 AM | americanbankingnews.comOrganon (OGN) Stock Slides as Market Rises: Facts to Know Before You TradeOctober 6 at 7:01 PM | zacks.comWill Organon (OGN) Beat Estimates Again in Its Next Earnings Report?October 6 at 1:11 PM | zacks.comPublic Employees Retirement System of Ohio Sells 23,948 Shares of Organon & Co. $OGNOctober 6 at 3:18 AM | marketbeat.comOrganon & Co. (NYSE:OGN) Receives Average Rating of "Moderate Buy" from AnalystsOctober 3, 2025 | marketbeat.comOrganon & Co. $OGN Shares Acquired by Cantor Fitzgerald Investment Advisors L.P.October 2, 2025 | marketbeat.comOrganon & Co. $OGN Shares Purchased by State of Alaska Department of RevenueOctober 1, 2025 | marketbeat.comOrganon & Co. $OGN Stake Lessened by Sound Income Strategies LLCSeptember 30, 2025 | marketbeat.comDakota Wealth Management Has $151,000 Stock Position in Organon & Co. $OGNSeptember 30, 2025 | marketbeat.comOrganon (OGN) Outperforms Broader Market: What You Need to KnowSeptember 29, 2025 | zacks.comSterneck Capital Management LLC Makes New Investment in Organon & Co. $OGNSeptember 28, 2025 | marketbeat.comRegister Financial Advisors LLC Sells 30,706 Shares of Organon & Co. $OGNSeptember 27, 2025 | marketbeat.comHere's Why Organon (OGN) Fell More Than Broader MarketSeptember 25, 2025 | zacks.comHere is What to Know Beyond Why Organon & Co. (OGN) is a Trending StockSeptember 24, 2025 | zacks.comOrogen Royalties' Exploration Stage Project and Royalty UpdateSeptember 24, 2025 | accessnewswire.comAOrganon (OGN) Stock Dips While Market Gains: Key FactsSeptember 19, 2025 | zacks.comEuropean Commission (EC) Approves Henlius and Organon's BILDYOS® (denosumab) and BILPREVDA® (denosumab), Biosimilars to PROLIA (denosumab) and XGEVA (denosumab), RespectivelySeptember 19, 2025 | businesswire.comWedmont Private Capital Acquires 106,561 Shares of Organon & Co. $OGNSeptember 19, 2025 | marketbeat.comGilman Hill Asset Management LLC Has $1.97 Million Stock Holdings in Organon & Co. $OGNSeptember 18, 2025 | marketbeat.comTriumph Capital Management Grows Stock Position in Organon & Co. $OGNSeptember 17, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesAfter the Fed's Rate Cut, PNC Could See a Mortgage Refinance BoomBy Jordan Chussler | September 21, 2025FedEx Delivers Good News: The Bottom Is in for This StockBy Thomas Hughes | September 19, 2025Airlines Are Taking Off, With More Gains Left to Price InBy Gabriel Osorio-Mazilli | September 25, 2025Cybersecurity Market Set to Double: This ETF Offers ExposureBy Jordan Chussler | September 24, 2025Why Traders Are Doubling Down on SoundHound Stock After Big RallyBy Gabriel Osorio-Mazilli | September 25, 2025NRIX, OGN, MOR, and KNSA Company DescriptionsKiniksa Pharmaceuticals International NASDAQ:KNSA$38.47 +0.35 (+0.92%) As of 02:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.MorphoSys NASDAQ:MOR$18.96 0.00 (0.00%) As of 10/7/2025MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.Nurix Therapeutics NASDAQ:NRIX$9.99 +0.16 (+1.63%) As of 02:12 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc., Sanofi S.A., and Seagen Inc. co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Francisco, California.Organon & Co. NYSE:OGN$10.24 -0.37 (-3.44%) As of 02:13 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Archer Aviation Stock Is Soaring—And What Comes Next Lithium Americas: Why This 31% Rally Is More Than Just a Headline Energy Transfer's New Growth Engine Ignites Investor Interest AMD Could Double From Here—Thanks to Its Blockbuster OpenAI Deal AMD and OpenAI: A Partnership That Just Redrew the AI Map EA’s $55 Billion Deal Spurs a Shake-Up in the Gaming Sector 3 Dividend Aristocrats to Buy Before Year’s End Will Firefly’s $855M SciTec Acquisition Ignite a Stock Re-Rating? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
